Patient Navigator Program

患者导航程序

基本信息

批准号：
7498915
负责人：
RICHARD G ROETZHEIM
金额：
$ 71.7万
依托单位：
H. LEE MOFFITT CANCER CTR & RES INST
依托单位国家：
美国
项目类别：
财政年份：
2005
资助国家：
美国
起止时间：
2005-09-29 至 2010-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7498915
关键词：
African American Age American Cancer Society Bay Region Biometry Breast Cancer Center Caring Client satisfaction Clinic Clinics and Hospitals Communities Community Health Community Hospitals Community Medicine Comprehensive Cancer Center Data Diagnosis Early Diagnosis Economics Education Educational Background Effectiveness Effectiveness of Interventions Evaluation Florida Goals Health Promotion Hispanics Incidence Intervention Knowledge Lead Life Living Costs Malignant Neoplasms Medical Metric Monitor Outcome Outcome Study Participant Patients Phase Population Heterogeneity Poverty Preparation Process Program Sustainability Provider Psychology Public Health Public Health Practice Quality of life Race Randomized Randomized Controlled Trials Rate Research Research Institute Screening procedure Societies Survival Rate Time Translating Underserved Population Work base cancer care cancer health disparity cancer risk cancer therapy care systems colorectal cancer screening cost cost effectiveness design expectation high school improved member mortality programs research and development socioeconomics

项目摘要

DESCRIPTION (provided by applicant): The elimination of cancer disparities is a national imperative that requires the creation of accessible and beneficial interventions. The Tampa Bay region of west central Florida epitomizes this challenge, with low levels of education (20% without a high school education), high levels of poverty (12.5% living below the poverty line), a culturally diverse population (18 percent Hispanic and 15 percent African American), and high cancer incidence and mortality rates. Our hypothesis is that a culturally appropriate patient navigator program can be implemented in the Tampa Bay region of Florida that .will decrease delay in diagnosis and delivery of cancer care in an acceptable and cost-effective manner. Our plan is based upon a partnership that includes an NCI designated comprehensive cancer center (H. Lee Moffitt Cancer Center & Research Institute), community hospitals and clinics, the American Cancer Society, and HealthChoice Network. In Phase I we will work closely with our community partners to conduct formative research for the development of an acceptable, appealing, and appropriate Patient Navigator Program/During Phase I we will also obtain baseline data, through chart abstraction, on timeliness and cost of cancer care. Phase II is a group randomized controlled trial to evaluate the Patient Navigator Program. We will focus on patients diagnosed with a breast or colorectal cancer screening abnormality within our participating network. Four centers will receive the Navigator Program, and three will receive the intervention, but delayed. Data will be collected at the time of an abnormal screening finding, and at 1 month, 6 month, 1 year and 2 years to monitor timeliness of care, appropriateness of care, and patient satisfaction and quality of life. Phase III calls for the dissemination of the findings from this research outside the Tampa Bay region. We will Use study outcome data, including results of cost-effectiveness analyses plus input from key stakeholders (participants and providers) to develop a plan for long-term dissemination and sustainability of the program. This study is expected to result in a comprehensive evaluation of a Patient Navigator Program on quality of cancer care, patient satisfaction, quality of life and cost-effectiveness. Such knowledge is essential to improvements in reducing the mortality and suffering from cancer by 2015

描述（由申请人提供）：消除癌症差异是国家当务之急，需要制定可行且有益的干预措施。佛罗里达州中西部的坦帕湾地区是这一挑战的集中体现，该地区教育水平低（20% 没有高中学历）、贫困程度高（12.5% 生活在贫困线以下）、文化多样化（18% 为西班牙裔和15% 为非洲裔美国人），癌症发病率和死亡率很高。我们的假设是，可以在佛罗里达州坦帕湾地区实施适合文化的患者导航计划，这将以可接受且具有成本效益的方式减少诊断和提供癌症护理的延误。我们的计划基于合作伙伴关系，其中包括 NCI 指定的综合癌症中心（H. Lee Moffitt 癌症中心和研究所）、社区医院和诊所、美国癌症协会和 HealthChoice Network。在第一阶段，我们将与社区合作伙伴密切合作，进行形成性研究，以开发可接受的、有吸引力的和适当的患者导航计划/在第一阶段，我们还将通过图表抽象获得有关癌症的及时性和成本的基线数据关心。 II 期是一项评估患者导航计划的随机对照试验。我们将重点关注我们参与网络中被诊断患有乳腺癌或结直肠癌筛查异常的患者。四个中心将接受导航计划，三个中心将接受干预，但会延迟。将在筛查发现异常时以及 1 个月、6 个月、1 年和 2 年收集数据，以监测护理的及时性、护理的适当性以及患者满意度和生活质量。第三阶段要求在坦帕湾地区以外传播这项研究的结果。我们将使用研究结果数据，包括成本效益分析结果以及主要利益相关者（参与者和提供者）的意见来制定该计划的长期传播和可持续性计划。这项研究预计将对患者导航计划的癌症护理质量、患者满意度、生活质量和成本效益进行全面评估。这些知识对于到 2015 年降低癌症死亡率和患病率至关重要